127 related articles for article (PubMed ID: 34125517)
21. Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine model.
Tan ML; Friedhuber AM; Dass CR
J Pharm Pharmacol; 2013 Jan; 65(1):35-43. PubMed ID: 23215686
[TBL] [Abstract][Full Text] [Related]
22. Checkpoint Blockade in Combination With Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma.
Wang J; Hu C; Wang J; Shen Y; Bao Q; He F; Wang H; Gong L; Liu Z; Hu F; Liang J; Zhou Q; Wei L; Wen J; Zhang W
J Immunother; 2019; 42(9):321-330. PubMed ID: 31219973
[TBL] [Abstract][Full Text] [Related]
23. Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.
Gazzano E; Buondonno I; Marengo A; Rolando B; Chegaev K; Kopecka J; Saponara S; Sorge M; Hattinger CM; Gasco A; Fruttero R; Brancaccio M; Serra M; Stella B; Fattal E; Arpicco S; Riganti C
Cancer Lett; 2019 Aug; 456():29-39. PubMed ID: 31047947
[TBL] [Abstract][Full Text] [Related]
24. Enhancing osteosarcoma therapy through aluminium hydroxide nanosheets-enabled macrophage modulation.
Cheng M; Jiang Y; Wang Y; Wu Y; Zhu Y
Int J Pharm; 2024 Jan; 649():123640. PubMed ID: 38043749
[TBL] [Abstract][Full Text] [Related]
25. Biomimetic Nucleation of Metal-Organic Frameworks on Silk Fibroin Nanoparticles for Designing Core-Shell-Structured pH-Responsive Anticancer Drug Carriers.
Chen Y; Wu H; Yang T; Zhou G; Chen Y; Wang J; Mao C; Yang M
ACS Appl Mater Interfaces; 2021 Oct; 13(40):47371-47381. PubMed ID: 34582680
[TBL] [Abstract][Full Text] [Related]
26. Combinational delivery of anticancer drugs for osteosarcoma treatment using electrosprayed core shell nanocarriers.
Prasad SR; Jayakrishnan A; Kumar TSS
J Mater Sci Mater Med; 2020 May; 31(5):44. PubMed ID: 32367204
[TBL] [Abstract][Full Text] [Related]
27. Efficient VEGF targeting delivery of DOX using Bevacizumab conjugated SiO
Zhu R; Wang Z; Liang P; He X; Zhuang X; Huang R; Wang M; Wang Q; Qian Y; Wang S
Acta Biomater; 2017 Nov; 63():163-180. PubMed ID: 28923539
[TBL] [Abstract][Full Text] [Related]
28. Targeted osteosarcoma chemotherapy using RGD peptide-installed doxorubicin-loaded biodegradable polymeric micelle.
Fang Z; Sun Y; Xiao H; Li P; Liu M; Ding F; Kan W; Miao R
Biomed Pharmacother; 2017 Jan; 85():160-168. PubMed ID: 27930982
[TBL] [Abstract][Full Text] [Related]
29. Synergistic anti-tumour activity of ginsenoside Rg3 and doxorubicin on proliferation, metastasis and angiogenesis in osteosarcoma by modulating mTOR/HIF-1α/VEGF and EMT signalling pathways.
Zeng X; Liu S; Yang H; Jia M; Liu W; Zhu W
J Pharm Pharmacol; 2023 Nov; 75(11):1405-1417. PubMed ID: 37498992
[TBL] [Abstract][Full Text] [Related]
30. Smart Biomimetic Nanocomposites Mediate Mitochondrial Outcome through Aerobic Glycolysis Reprogramming: A Promising Treatment for Lymphoma.
Zhao Q; Li J; Wu B; Shang Y; Huang X; Dong H; Liu H; Chen W; Gui R; Nie X
ACS Appl Mater Interfaces; 2020 May; 12(20):22687-22701. PubMed ID: 32330381
[TBL] [Abstract][Full Text] [Related]
31. An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model.
Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Kanaya F; Nishida K; Hoffman RM
Sci Rep; 2021 Apr; 11(1):8583. PubMed ID: 33883561
[TBL] [Abstract][Full Text] [Related]
32. Phosphate-Degradable Nanoparticles Based on Metal-Organic Frameworks for Chemo-Starvation-Chemodynamic Synergistic Antitumor Therapy.
Peng H; Qin YT; Feng YS; He XW; Li WY; Zhang YK
ACS Appl Mater Interfaces; 2021 Aug; 13(31):37713-37723. PubMed ID: 34340302
[TBL] [Abstract][Full Text] [Related]
33. TPGS-Galactose-Modified Polydopamine Co-delivery Nanoparticles of Nitric Oxide Donor and Doxorubicin for Targeted Chemo-Photothermal Therapy against Drug-Resistant Hepatocellular Carcinoma.
Du Z; Mao Y; Zhang P; Hu J; Fu J; You Q; Yin J
ACS Appl Mater Interfaces; 2021 Aug; 13(30):35518-35532. PubMed ID: 34286569
[TBL] [Abstract][Full Text] [Related]
34. Doxorubicin vs. ladirubicin: methods for improving osteosarcoma treatment.
Soares PI; Dias SJ; Novo CM; Ferreira IM; Borges JP
Mini Rev Med Chem; 2012 Oct; 12(12):1239-49. PubMed ID: 22512558
[TBL] [Abstract][Full Text] [Related]
35. Dual targeting curcumin loaded alendronate-hyaluronan- octadecanoic acid micelles for improving osteosarcoma therapy.
Xi Y; Jiang T; Yu Y; Yu J; Xue M; Xu N; Wen J; Wang W; He H; Shen Y; Chen D; Ye X; Webster TJ
Int J Nanomedicine; 2019; 14():6425-6437. PubMed ID: 31496695
[TBL] [Abstract][Full Text] [Related]
36. Radiation improves the distribution and uptake of liposomal doxorubicin (caelyx) in human osteosarcoma xenografts.
Davies Cde L; Lundstrøm LM; Frengen J; Eikenes L; Bruland S ØS; Kaalhus O; Hjelstuen MH; Brekken C
Cancer Res; 2004 Jan; 64(2):547-53. PubMed ID: 14744768
[TBL] [Abstract][Full Text] [Related]
37. In Vivo Targeting and Positron Emission Tomography Imaging of Tumor with Intrinsically Radioactive Metal-Organic Frameworks Nanomaterials.
Chen D; Yang D; Dougherty CA; Lu W; Wu H; He X; Cai T; Van Dort ME; Ross BD; Hong H
ACS Nano; 2017 Apr; 11(4):4315-4327. PubMed ID: 28345871
[TBL] [Abstract][Full Text] [Related]
38. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
[TBL] [Abstract][Full Text] [Related]
39. PEDF-derived synthetic peptides exhibit antitumor activity in an orthotopic model of human osteosarcoma.
Ek ET; Dass CR; Contreras KG; Choong PF
J Orthop Res; 2007 Dec; 25(12):1671-80. PubMed ID: 17600821
[TBL] [Abstract][Full Text] [Related]
40. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
